Investigating the Properties and Cytotoxicity of Cisplatin-Loaded Nano-Polybutylcyanoacrylate on Breast Cancer Cells

Authors

  • Amirsasan Gorgzadeh Faculty of Pharmacy, Jundi Shapour University, Ahvaz, Iran.
  • Ali Hheidari Department of Mechanical Engineering, Islamic Azad University, Science and Research Branch, Tehran, Iran.
  • Parizad Ghanbarikondori Department of Pharmaceutics, Pharmaceutical Sciences Branch, Islamic Azad University (IAU), Tehran, Iran.
  • Mahshid Arastonejad Department of Human and Molecular, Genetics, Virginia Commonwealth University, Richmond, VA, United States.
  • Tayebeh Ghasemi Goki Department of Nursing and Midwifery, Kerman Branch, Islamic Azad University, Kerman, Iran.
  • Mehrad Aria Department of Medical Informatics, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadreza Allahyartorkaman Department of Clinical Science, Faculty of Veterinary Medicine, Islamic Azad University (IAU), Garmsar branch, Semnan, Iran.
  • Farimah Moazzam Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Zeinab Jabbari Velisdeh Department of Chemical Engineering, Babol Noshirvani University of Technology, Babol, Iran.
  • Elham Saberian MDDr., PhD and Specialty Student, Pavol Jozef Šafárik University, Klinika and Akadémia Košice Bacikova, Kosice, Slovakia.
  • Ali Habiba School of mechanical engineering, college of engineering, University of Tehran, North Kargar street, Tehran, Iran.
  • Paniz Mirmoghaddam Islamic Azad university of medical science, Mashhad, Iran.
  • Somayeh Eslami Mahan Research Centre, Mahan Pain Clinic, Tehran, Iran.
  • Armin Sedighi Department of Electrical Engineering, Islamic Azad University, Science and Research Branch, Qazvin, Iran.

Keywords:

Cisplatin - Polybutylcyanoacrylate - breast cancer - T-47D cells

Abstract

Background: This study aimed to develop a novel drug formulation using polybutylcyanoacrylate (PBCA) nanoparticles to deliver cisplatin, a commonly used chemotherapeutic agent for breast cancer treatment.
Materials and Methods: PBCA nanoparticles were synthesized using a mini-emulsion polymerization method, and the resulting NPs were comprehensively characterized for their physical properties, such as size, size distribution, zeta potential, drug loading, and encapsulation efficiency. In addition, the cytotoxicity of the NPs was assessed, along with their ability to release the entrapped drugs over time.
Results: The results showed that the PBCA nanoparticles had a mean size of 457 ± 7.4 nm, a size distribution of 0.253±0.011 and a negative zeta potential of -12.3 ± 1.3 mV. The drug encapsulation efficiency and loading capacity of cisplatin-PBCA were found to be 45.6 ± 2.7% and 3.5 ±0.8%, respectively; The release of the drug from the PBCA was estimated to be approximately 12.2±1.1% after 45 hours. The cytotoxic effects of the nanoparticle formulation were significantly enhanced compared to the free drug. The cytotoxicity of cisplatin-PBCA was evaluated in the T-47D breast cancer cell line, showing promising results as a potential drug formulation for breast cancer therapy.
Conclusions: These findings suggest that cisplatin-PBCA may offer advantages over traditional cisplatin formulations, potentially improving the efficacy and reducing the toxicity of breast cancer treatment.

Downloads

Published

2023-11-06

Issue

Vol. 8 No. 4 (2023)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).